# CBD and Epilepsy: From FDA Approval to Clinical Practice (2025)

## Introduction

Epilepsy affects over 50 million people worldwide, making it one of the most common neurological conditions. For approximately 30% of patients, seizures remain uncontrolled despite optimal treatment with conventional antiseizure medications. This treatment-resistant population faces significant challenges, including cognitive impairment, injury risk, and reduced quality of life.

Cannabidiol (CBD) represents a landmark achievement in epilepsy treatment, becoming the first cannabis-derived medication approved by the FDA. Unlike many breakthrough therapies that emerge from targeted drug design, CBD's path from ancient remedy to modern pharmaceutical exemplifies the potential of natural compounds in evidence-based medicine. This comprehensive review examines the current state of CBD for epilepsy treatment, from molecular mechanisms to real-world outcomes, based on the latest evidence through 2025.

## The Science Behind CBD's Antiseizure Effects

### Unique Mechanisms of Action

CBD's anticonvulsant properties operate through mechanisms distinct from both conventional antiseizure medications and other cannabinoids [[1]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7604476/):

**Non-Cannabinoid Receptor Pathways**: Unlike THC, CBD does not activate cannabinoid receptors but instead interacts with several other signaling systems, making it non-intoxicating while maintaining therapeutic effects.

**TRPV1 Modulation**: Research suggests TRPV1-mediated signaling plays a primary role in CBD's anticonvulsant effects, particularly in reducing neuronal hyperexcitability.

**GPR55 Antagonism**: CBD blocks GPR55, sometimes called the "third cannabinoid receptor," which may contribute to seizure control.

**Adenosine Enhancement**: By inhibiting adenosine reuptake, CBD increases this endogenous anticonvulsant.

**5-HT1A Receptor Agonism**: Serotonergic effects may contribute to both seizure control and behavioral improvements.

### Neuroinflammation and Neuroprotection

Beyond direct anticonvulsant effects:
- Reduces pro-inflammatory cytokines in epileptic brain tissue
- Protects against oxidative stress-induced neuronal damage
- May prevent epileptogenesis in certain models
- Preserves mitochondrial function during seizures

## Clinical Evidence: From Trials to Practice

### Landmark Clinical Trials

**Dravet Syndrome** [[2]](https://pubmed.ncbi.nlm.nih.gov/37769547/):
- **GWPCARE1**: 43% achieved ≥50% seizure reduction vs 27% placebo
- **Seizure Freedom**: 5% became completely seizure-free
- **Convulsive Seizures**: Median reduction of 39%

**Lennox-Gastaut Syndrome** [[3]](https://pmc.ncbi.nlm.nih.gov/articles/PMC9683917/):
- **Drop Seizures**: 37.2% reduction (10mg/kg) and 41.9% reduction (20mg/kg)
- **Total Seizures**: Significant reduction across all seizure types
- **Response Rate**: 44% achieved ≥50% reduction in drop seizures

**Tuberous Sclerosis Complex** [[4]](https://pubmed.ncbi.nlm.nih.gov/40673944/):
- **Focal Seizures**: 51-87% median reduction
- **Total Seizures**: 44-87% median reduction
- **FDA Approval**: Granted based on phase 3 trial success

### Recent Meta-Analyses (2023-2025)

**2023 Pediatric Meta-Analysis** [[5]](https://pubmed.ncbi.nlm.nih.gov/36206805/):
- 6 high-quality RCTs analyzed
- Overall efficacy OR = 2.45 (95% CI = 1.81-3.32, p < 0.01)
- Dravet: OR = 2.26
- Lennox-Gastaut: OR = 2.98
- TSC: OR = 1.99

**2025 Systematic Review** [[6]](https://aepi.biomedcentral.com/articles/10.1186/s42494-024-00191-2):
- Consistent seizure reduction across all studies
- Number needed to treat = 8 for ≥50% seizure reduction
- Dose-dependent efficacy observed

### Real-World Evidence

**Expanded Access Program Results** [[7]](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-present-extensive-new-data-and-real-world):
- Mean seizure reduction: 67.8%
- ≥50% responder rate: 68.8%
- Seizure freedom: 11.5%
- Sustained benefits over 2+ years

**BECOME Survey (2024)**:
- 85% of nurses reported overall seizure reduction
- 49% reported >50% reduction
- Improvements in non-seizure outcomes:
  - Emotional functioning (71%)
  - Sleep quality (68%)
  - Cognitive abilities (65%)
  - Communication (62%)

## Beyond Traditional Indications

### Emerging Epilepsy Syndromes

Open-label studies show promise for [[8]](https://link.springer.com/article/10.1186/s42466-025-00408-w):
- CDKL5 deficiency disorder
- Aicardi syndrome
- Dup15q syndrome
- Doose syndrome
- SYNGAP1 encephalopathy
- Epilepsy with myoclonic absences

### Focal Epilepsies

**EpiFOS Study (Ongoing)**:
- Exploring efficacy in focal-onset seizures
- NCT07233239 currently recruiting
- May expand indications significantly

### Non-Seizure Benefits

Recent data highlights improvements beyond seizure control:
- **Behavior**: Reduced aggression and self-injury
- **Sleep**: Better sleep architecture and duration
- **Cognition**: Enhanced attention and processing speed
- **Quality of Life**: Improved family functioning

## Dosing and Administration

### Standard Protocols

**Initial Dosing**:
- Starting: 2.5 mg/kg twice daily
- Titration: Increase by 2.5 mg/kg/dose weekly
- Maintenance: 10-20 mg/kg/day (divided BID)
- Maximum: 50 mg/kg/day if tolerated

**Administration Tips**:
- Take with high-fat meal (14-fold increase in absorption)
- Consistent timing for steady levels
- Oral solution: 100 mg/mL concentration
- Store at room temperature

### Special Populations

**Hepatic Impairment**:
- Mild: No adjustment
- Moderate: Reduce dose
- Severe: More significant reduction needed

**Drug Interactions Requiring Dose Adjustment**:
- With valproate: Start lower, monitor liver enzymes
- With clobazam: May need clobazam dose reduction
- CYP inducers: May need higher CBD doses

## Drug Interactions and Monitoring

### Significant Interactions

**CYP450 Inhibition** [[1]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7604476/):
- **Clobazam**: 60% increase in levels; N-desmethylclobazam up to 500%
- **Increases Levels Of**: Zonisamide, eslicarbazepine, topiramate, rufinamide
- **No Effect On**: Valproic acid, stiripentol, levetiracetam
- **Reduced By**: Phenytoin, carbamazepine

### Monitoring Requirements

**Baseline**:
- Liver function tests (ALT, AST)
- Complete blood count
- Current AED levels

**Ongoing**:
- LFTs at 1, 3, 6 months, then periodically
- More frequent with valproate co-therapy
- AED levels if clinical changes
- Weight/growth in pediatric patients

## Safety Profile

### Common Adverse Events

From pooled clinical trial data:
- Somnolence (23-25%)
- Decreased appetite (16-20%)
- Diarrhea (15-20%)
- Fatigue (11-12%)
- Vomiting (8-10%)
- Pyrexia (8%)

### Serious Considerations

**Hepatotoxicity**:
- Transaminase elevation in 16% (vs 3% placebo)
- Higher risk with valproate
- Usually reversible with dose reduction
- Rare cases of significant elevation

**Other Serious Events**:
- Status epilepticus (rare, possibly related to rapid withdrawal)
- Hypersensitivity reactions (very rare)
- Suicidal ideation (similar to other AEDs)

### Long-Term Safety

**2+ Year Data**:
- No new safety signals
- Tolerance does not develop
- No withdrawal syndrome
- Growth/development normal in pediatric patients

## Cost and Access Considerations

### Financial Burden

**Average Costs (2025)**:
- Epidiolex: $32,500-65,000/year
- Insurance coverage: Variable
- Patient assistance programs available
- Generic CBD not equivalent

### Access Programs

**Manufacturer Support**:
- Jazz Pharmaceuticals patient assistance
- Co-pay assistance for eligible patients
- Free drug programs for qualifying families

**Insurance Navigation**:
- Prior authorization typically required
- Appeals process often necessary
- Documentation of failed therapies needed

## Practical Clinical Guidelines

### Patient Selection

**Ideal Candidates**:
- Confirmed Dravet, LGS, or TSC diagnosis
- Failed ≥2 appropriate AEDs
- No significant hepatic impairment
- Able to comply with monitoring

**Relative Contraindications**:
- Severe hepatic disease
- Hypersensitivity to sesame oil (in formulation)
- Concurrent medications with narrow therapeutic index

### Starting Treatment

1. **Baseline Assessment**: Seizure diary, labs, quality of life measures
2. **Education**: Proper administration, expected timeline, side effects
3. **Slow Titration**: Minimize side effects, assess response
4. **Early Monitoring**: Weekly contact first month
5. **Optimization**: Adjust based on response and tolerability

## Future Directions and Research

### Ongoing Trials

- Focal epilepsy indications
- Neonatal seizures
- Status epilepticus
- Combination with other novel AEDs
- Precision medicine approaches

### Mechanistic Research

- Biomarkers for response prediction
- Optimal timing in disease course
- Neuroprotective potential
- Disease-modifying effects

### Formulation Development

- Extended-release preparations
- Alternative delivery routes
- Improved bioavailability
- Synthetic analogues

## Frequently Asked Questions

### 1. How does Epidiolex differ from CBD oil I can buy online?
Epidiolex is pharmaceutical-grade CBD with consistent purity, concentration, and manufacturing standards. Over-the-counter CBD products vary widely in quality, may contain THC, and lack the rigorous testing required for FDA approval. Only Epidiolex is proven effective for epilepsy.

### 2. How quickly will I see results?
Most patients show response within 2-4 weeks, though full benefits may take 3 months. The BECOME survey found 85% of patients showed improvement by 12 weeks. Unlike some AEDs, benefits don't typically diminish over time.

### 3. Can CBD cure epilepsy?
No, CBD is not a cure. While 5-15% of patients may achieve seizure freedom, most experience seizure reduction rather than elimination. It's an important addition to treatment options but not a replacement for comprehensive epilepsy care.

### 4. What happens if I miss a dose?
Take the missed dose as soon as remembered unless it's close to the next dose. Don't double up. Consistent dosing is important for maintaining steady blood levels and seizure control.

### 5. Can I use CBD with the ketogenic diet?
Yes, many patients use both therapies together. Some studies suggest synergistic effects. The high-fat ketogenic diet may actually enhance CBD absorption. Monitor for increased side effects.

### 6. Will CBD affect my child's development?
Long-term studies show no negative effects on growth or development. Many patients show cognitive improvements, possibly due to better seizure control. Regular monitoring ensures any issues are caught early.

### 7. How do I know if the dose is too high?
Excessive sedation, persistent diarrhea, or elevated liver enzymes suggest the dose may be too high. Most side effects are dose-related and improve with reduction. Work with your provider to find the optimal dose.

### 8. Can I stop other medications once starting CBD?
Never stop other AEDs without medical supervision. CBD is approved as add-on therapy. Some patients may eventually reduce other medications, but this requires careful monitoring and gradual adjustment.

### 9. Is CBD safe during pregnancy?
Limited data exists for pregnancy. Animal studies suggest potential risks. Current recommendations advise against use during pregnancy unless benefits clearly outweigh risks. Discuss with maternal-fetal medicine specialists.

### 10. Will insurance cover Epidiolex?
Coverage varies but is improving. Most plans cover for FDA-approved indications with prior authorization. The appeals process is often successful with proper documentation. Patient assistance programs can help with costs.

## Conclusion

CBD represents a transformative development in epilepsy treatment, offering hope to patients with previously intractable seizures. The journey from botanical curiosity to FDA-approved medication exemplifies rigorous drug development, with multiple controlled trials confirming efficacy for specific epilepsy syndromes.

The evidence is particularly robust for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, where CBD provides meaningful seizure reduction in 40-70% of patients. Real-world data confirms these benefits extend beyond clinical trials, with sustained efficacy and improvements in non-seizure outcomes that significantly impact quality of life.

However, CBD is not a panacea. Response varies considerably, side effects require monitoring, and cost remains a significant barrier. The expansion to other epilepsy types continues through ongoing research, with promising signals for broader applications.

For clinicians, CBD offers a valuable tool with a unique mechanism of action, particularly useful for patients who have exhausted other options. Success requires appropriate patient selection, careful titration, vigilant monitoring, and realistic expectations. As our understanding deepens and access improves, CBD will likely play an increasingly important role in comprehensive epilepsy care.

The story of CBD in epilepsy demonstrates the importance of studying natural compounds with scientific rigor, the value of patient advocacy in driving research, and the potential for transforming ancient remedies into modern medicines. For the thousands of patients now experiencing better seizure control and improved quality of life, CBD represents not just a medication, but renewed hope for fuller participation in life's activities.

---

*Written by Robin Roy Krigslund-Hansen*

*Robin Roy Krigslund-Hansen has worked in the CBD and cannabis industry since 2013. Based in Switzerland, he focuses on translating clinical research into accessible information for consumers. His approach prioritises peer-reviewed evidence and regulatory developments across European markets.*

---

*This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any new supplement regimen, especially if you have existing health conditions or take medications.*

## References

1. Perucca E. Cannabinoids in the Treatment of Epilepsy: A Focused Review of Evidence and Gaps. Front Neurol. 2020;11:531939. [PMC7604476](https://pmc.ncbi.nlm.nih.gov/articles/PMC7604476/)

2. Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy. Epilepsy Behav. 2023. [PMID: 37769547](https://pubmed.ncbi.nlm.nih.gov/37769547/)

3. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Epilepsy Behav. 2022. [PMC9683917](https://pmc.ncbi.nlm.nih.gov/articles/PMC9683917/)

4. Long-term efficacy and safety of cannabidiol in patients with treatment-resistant focal epilepsies. Epilepsia. 2025. [PMID: 40673944](https://pubmed.ncbi.nlm.nih.gov/40673944/)

5. Chen KA, et al. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Ther Med. 2023;25(1):18. [PMID: 36206805](https://pubmed.ncbi.nlm.nih.gov/36206805/)

6. The efficacy of cannabidiol for seizures reduction in pharmacoresistant epilepsy: a systematic review and meta-analysis. Acta Epileptologica. 2025. [Available at BioMed Central](https://aepi.biomedcentral.com/articles/10.1186/s42494-024-00191-2)

7. Jazz Pharmaceuticals. Extensive New Data and Real-World Evidence Highlighting Epidiolex Outcomes. 2025. [Available at Jazz Pharma](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-present-extensive-new-data-and-real-world)

8. Use of cannabidiol for off-label treatment of patients with refractory focal, genetic generalised and other epilepsies. Neurol Res Pract. 2025. [Available at Springer](https://link.springer.com/article/10.1186/s42466-025-00408-w)